Acute myeloid leukemia pediatric · 19 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
COG AAML0531 arm B (Gemtuzumab) N/A - intrathecal component Partial | — | R 341 397 | 28d | — | — | 1 | R 341 397 PFS proxy | 1 |
COG AAML1031 arm A (high-risk) N/A - intrathecal component Partial | — | R 155 859 | 28d | — | — | ~1 | ~R 155 859 indirect | — |
COG AAML1031 arm C (FLT3/ITD+) N/A - intrathecal component | — | R 153 131 | 36d | — | — | ~1 | ~R 153 131 indirect | — |
COG AAML1031 arm A (low-risk) N/A - intrathecal component | — | R 113 567 | 10d | — | — | ~1 | ~R 113 567 indirect | — |
ADE and GO Variant #01 | — | R 56 671 | 10d | — | — | 1 | R 56 671 PFS proxy | 1 |
DA 3+10, GO Variant #01 | — | R 54 619 | 10d | — | — | ~1 | ~R 54 619 PFS proxy · indirect | 1 |
FLAG-Ida Variant #01 | — | R 48 325 | 28d | — | ~5.4 mo | ~1 | ~R 48 325 PFS proxy · indirect | 3 |
ADE (high-dose Ara-C) Variant #01 | — | R 25 902 | 6d | — | — | ~1 | ~R 25 902 PFS proxy · indirect | 1 |
D-ZAPO Variant #01 | — | R 23 571 | 14d | — | — | ~4 | ~R 94 283 indirect | — |
DAT Variant #03 | — | R 21 422 | 9d | — | — | ~1 | ~R 21 422 indirect | — |
AIE Variant #01 | — | R 20 821 | 7d | — | — | ~1 | ~R 20 821 indirect | — |
ADE (standard-dose Ara-C) Variant #07 | — | R 13 353 | 10d | — | — | ~1 | ~R 13 353 PFS proxy · indirect | 2 |
DA 3+10 Variant #01 | — | R 11 640 | 10d | — | — | ~1 | ~R 11 640 PFS proxy · indirect | 2 |
DCTER Variant #01 | — | R 10 343 | 4d | — | — | ~1 | ~R 10 343 indirect | — |
MEC Variant #01 | — | R 9 564 | 28d | — | ~5.5 mo | ~1 | ~R 9 564 PFS proxy · indirect | 4 |
7+3d Variant #01 | — | R 6 538 | — | — | ~15.1 mo | ~2 | ~R 13 076 PFS proxy · indirect | 11 |
Mercaptopurine monotherapy Variant #01 | — | R 4 912 | — | — | — | ~1 | ~R 4 912 indirect | — |
Cytarabine, Doxorubicin, Vincristine, Prednisolone Variant #01 | — | R 3 778 | — | — | — | ~2 | ~R 3 816 indirect | — |
PATCO Variant #01 | — | R 2 737 | 14d | — | — | ~4 | ~R 10 946 indirect | — |
19 of 19 regimens shown